{"id":55946,"date":"2023-04-18T15:03:08","date_gmt":"2023-04-18T13:03:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/"},"modified":"2023-04-18T15:03:08","modified_gmt":"2023-04-18T13:03:08","slug":"headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/","title":{"rendered":"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases"},"content":{"rendered":"
\n

\nHeadlands Research Eastern Massachusetts deepens the neurology research expertise of the expanding multinational clinical trial site network<\/p>\n

SAN FRANCISCO–(BUSINESS WIRE)–#Alzheimersdisease<\/a>—Headlands Research<\/a>, a leading multinational network of clinical trial sites, today announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as Alzheimer\u2019s disease and Parkinson\u2019s disease for over 25 years.<\/p>\n

<\/a><\/p>\n

\n\u201cWith its longstanding focus on memory and movement disorders, Headlands Research Eastern Massachusetts strengthens the breadth and depth of our existing neurology specialty research,\u201d said Cathy Collins, CEO of Headlands Research. \u201cWe are proud to welcome Headlands Research Eastern Massachusetts to our expanding network of clinical trial sites, helping to make clinical trials \u2014 and the innovative therapies they provide \u2014 accessible to more people.\u201d<\/p>\n

\nHeadlands Research Eastern Massachusetts is led by founder and Principal Investigator (PI) Donald Marks, MD, a board-certified neurologist specializing in the diagnosis and treatment of Alzheimer\u2019s disease, Parkinson\u2019s disease, and related disorders who also currently serves on the staff of the Division of Neurology at Beth Israel Deaconess Hospital \u2013 Plymouth. Dr. Marks conducted his first clinical trial in 1993, evaluating tacrine, the first drug approved for the treatment of Alzheimer\u2019s disease, and in 2008, Dr. Marks and his team began research on disease-modifying drugs (DMDs) for Alzheimer\u2019s disease. To date, Dr. Marks and his team have conducted 41 clinical trials, with 36 focusing on Alzheimer\u2019s disease. The team has been in an accelerated growth phase \u2014 13 of the 36 Alzheimer\u2019s disease trials have been started since 2020.<\/p>\n

\n\u201cMy team and I are proud of our ability to provide compassionate care for patients and families facing the impact of neurodegenerative diseases. Through our research, we can help fill the gap in the availability of disease-modifying treatments and effective long-term symptomatic therapies,\u201d said Dr. Marks. \u201cJoining Headlands Research increases the number of clinical trials and innovative, investigational treatments available for our patient population.\u201d<\/p>\n

\nBy focusing on diversity, quality, and cutting-edge technology, the Headlands Research network of clinical research sites aims to improve people\u2019s lives by advancing innovative medical therapies. Headlands Research also recently announced<\/a> the launch of Headlands Research Detroit and has plans to continue expanding its network throughout 2023.<\/p>\n

\nTo learn more about Headlands Research and its extensive network of research sites, visit https:\/\/headlandsresearch.com<\/a>, contact info@headlandsresearch.com<\/a>, or follow the company on LinkedIn<\/a>.<\/p>\n

\nAbout Headlands Research<\/b><\/p>\n

\nHeadlands Research is a multinational integrated clinical trial site organization with a mission to improve people\u2019s lives by advancing innovative medical therapies. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research\u2019s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nBrittany Kearns
\n
Phone: <\/b>919-270-8054
\n
Email: <\/b>brittany@crossroadsb2b.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Headlands Research Eastern Massachusetts deepens the neurology research expertise of the expanding multinational clinical trial site network SAN FRANCISCO–(BUSINESS WIRE)–#Alzheimersdisease—Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55946","6":"format-standard","7":"category-industry"},"yoast_head":"\nHeadlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Headlands Research Eastern Massachusetts deepens the neurology research expertise of the expanding multinational clinical trial site network SAN FRANCISCO–(BUSINESS WIRE)–#Alzheimersdisease—Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T13:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230418005273\/en\/1765649\/21\/HEADLANDS_LOGO_WHITE.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases\",\"datePublished\":\"2023-04-18T13:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/\"},\"wordCount\":522,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005273\\\/en\\\/1765649\\\/21\\\/HEADLANDS_LOGO_WHITE.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/\",\"name\":\"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005273\\\/en\\\/1765649\\\/21\\\/HEADLANDS_LOGO_WHITE.jpg\",\"datePublished\":\"2023-04-18T13:03:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005273\\\/en\\\/1765649\\\/21\\\/HEADLANDS_LOGO_WHITE.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005273\\\/en\\\/1765649\\\/21\\\/HEADLANDS_LOGO_WHITE.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases - Pharma Trend","og_description":"Headlands Research Eastern Massachusetts deepens the neurology research expertise of the expanding multinational clinical trial site network SAN FRANCISCO–(BUSINESS WIRE)–#Alzheimersdisease—Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-18T13:03:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230418005273\/en\/1765649\/21\/HEADLANDS_LOGO_WHITE.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases","datePublished":"2023-04-18T13:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/"},"wordCount":522,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005273\/en\/1765649\/21\/HEADLANDS_LOGO_WHITE.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/","url":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/","name":"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005273\/en\/1765649\/21\/HEADLANDS_LOGO_WHITE.jpg","datePublished":"2023-04-18T13:03:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230418005273\/en\/1765649\/21\/HEADLANDS_LOGO_WHITE.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230418005273\/en\/1765649\/21\/HEADLANDS_LOGO_WHITE.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/headlands-research-acquires-established-eastern-massachusetts-based-research-site-specializing-in-neurodegenerative-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Headlands Research Acquires Established Eastern Massachusetts\u2013Based Research Site Specializing in Neurodegenerative Diseases"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55946"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55946\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}